Alkem Laboratories Limited has announced the launch of semaglutide in single-shot pre-filled syringes, becoming the first pharmaceutical company in India to introduce the therapy in this format. Available in multiple dosage strengths and priced from ₹350, the new offering is designed to improve accessibility and provide patients and healthcare professionals with greater treatment flexibility.
The launch marks another milestone in Alkem’s efforts to expand access to advanced therapies for the management of Type 2 diabetes mellitus and obesity. The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market the product as an adjunct to diet and exercise for eligible patients.
The ready-to-use single-shot pre-filled syringe has been developed to simplify administration and enhance convenience. By offering an affordable entry point and a user-friendly delivery system, Alkem aims to help more patients initiate and continue treatment for chronic metabolic conditions that continue to rise across India.
This latest introduction builds on the company’s earlier launch of semaglutide injection pens in March 2026. Those offerings included both disposable and reusable pen formats, providing physicians with multiple options tailored to patient needs. Alkem has also secured regulatory approval for semaglutide vials and plans to introduce that format in the near future, further broadening its portfolio.
Dr Vikas Gupta, Chief Executive Officer of Alkem Laboratories, said semaglutide has emerged as an important therapy in the management of metabolic disorders. He noted that the addition of pre-filled syringes expands the range of treatment choices available to doctors and patients while supporting improved access through practical and affordable delivery formats.
The launch comes at a time when India is witnessing a growing prevalence of diabetes, obesity, and related metabolic conditions. Healthcare providers increasingly emphasize early intervention, sustained treatment adherence, and patient-centric care models to improve long-term health outcomes.
Alkem Laboratories has built a strong presence in both acute and chronic therapy segments over the past five decades. The company currently ranks among India’s leading pharmaceutical manufacturers and maintains a diverse portfolio spanning anti-infectives, gastrointestinal therapies, pain management, cardiology, neurology, dermatology, urology, and diabetes care.
With 18 manufacturing facilities and advanced research and development centers across India and the United States, Alkem continues to invest in innovation, affordability, and quality. The introduction of semaglutide pre-filled syringes reflects the company’s commitment to expanding treatment access and supporting better healthcare outcomes for patients across India and global markets.
